GenesisCare announce new global leadership team
SYDNEY, Australia, 3 March 2023 – GenesisCare, one of the world’s largest providers of integrated cancer care with operations in Australia, UK, Spain and the USA, today announced that Dan Collins is leaving as Chief Executive Officer and Managing Director.
On behalf of the Board of Directors, Chairman Dr Michael Guiney said, “The Board is grateful for Dan’s vision and leadership over the last 18 years. During that time, Dan has led GenesisCare’s expansion of access to high quality patient care around the world, from a single practice in Brisbane to 440 practices across four countries. GenesisCare is now a global organisation delivering quality healthcare services to hundreds of thousands of patients each year. We would like to acknowledge Dan’s achievements in building GenesisCare into a world-class healthcare provider. We wish Dan all the very best for the future and we thank him for his contribution”.
“Notwithstanding that, the Board considers that after 18 years now is the right time for a leadership change at GenesisCare, particularly given the challenges facing the organisation and the healthcare sector more generally.”
The Board of Directors is advancing the appointment of the new CEO and Managing Director, with commencement anticipated within the next two months. In the interim, Michael O’Sullivan, Chief Operating Officer and Dr Shaden Marzouk, USA President, will assume responsibility for the day-to-day leadership of the business and will report directly to the Board during this transition. Michael will be responsible for all global shared services, our businesses in Australia, UK and Spain, and Shaden will continue to lead the USA business.
GenesisCare is the world’s largest provider of radiotherapy, a vital treatment option for cancer patients. GenesisCare also provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy and novel therapies alongside the opportunity to participate in the latest clinical trials. GenesisCare is committed to improving clinical outcomes through world class therapies.